UNITY Biotechnology, Inc. announced Gilmore O’Neill, M.B., has been appointed to the board of directors and as the chair of the science committee. This evolution of UNITY’s board composition reflects a continued focus on building a clinical-stage drug development company to advance its ophthalmology and neurology programs. Dr. O’Neill has more than 25 years of experience in drug development, and medical and regulatory affairs. He is currently chief medical officer and executive vice president of research and development at Sarepta Therapeutics. Previously, Dr. O’Neill spent 15 years at Biogen, holding leadership roles in development programs for Alzheimer’s disease, movement disorders, neurology, multiple sclerosis, pain, neuromuscular disease, gene and cell therapy, and rare diseases, and overseeing multiple global marketing approvals. Coincident with Dr. O’Neil’s appointment, Robert T. Nelsen and David L. Lacey, M.D., have left the board of directors. In a further reflection of the evolution of UNITY as a clinical stage company, Nathaniel (Ned) David, Ph.D., will step down as president effective December 31st, 2020. Dr. David, who co-founded UNITY in 2011 and has been instrumental in developing.